The Department of Health and Human Services has awarded Paratek Pharmaceuticals a potential a five-year, $169M contract to further develop an antibiotic drug as a potential treatment for inhalation anthrax.
Read More »
Emergent BioSolutions (NYSE: EBS) has received a potential two-year, $100 million contract from the Biomedical Advanced Research and Development Authority to deliver BioThrax anthrax vaccines to the Strategic National Stockpile. The award came three months after the Centers for Disease Control and Prevention awarded Emergent a potential $911 million follow-on contract to supply …
Read More » SRI International has received a pair of contracts worth a combined $90 million to help the Biomedical Advanced Research and Development Authority assess compounds that have potential to treat people exposed to chemical, biological, radiological or nuclear weapons. The company said Wednesday that both contracts have a base period of five years and cover …
Read More »
The Department of Health and Human Services has awarded Emergent BioSolutions a five-year, $198.7 million contract to further mature the development of an anthrax vaccine in preparation for a Food and Drug Administration license. The HHS office of the assistant secretary for preparedness and response’s Biomedical Advanced Research and Development …
Read More » The Department of Health and Human Services has awarded a potential $173.6 million contract to Sanofi Pasteur for work to develop inactivated vaccine candidate that could help prevent Zika virus infection and associated birth defects. HHS said Monday the contract has a $43.2 million base value that covers process development, scale up, clinical trial material production …
Read More » Altimmune has received a potential five-year, $120.2 million contract from the Biomedical Advanced Research and Development Authority to conduct clinical trials on an experimental vaccine against anthrax. The Gaithersburg, Maryland-based immunotherapeutic company will test its NasoShield intranasal anthrax vaccine through Phase 1 clinical studies under the contract’s base term worth approximately $14.3 …
Read More » The Biomedical Advanced Research and Development Authority has awarded Emergent BioSolutions (NYSE: EBS) a potential $21.9 million task order to develop and produce a vaccine against Zika virus for use in the first phase of a clinical trial. The company said Monday the order has a base period of 30 months …
Read More »
The Department of Health and Human Services has tapped Emergent BioSolutions to further develop a new anthrax vaccine under a 30-month, $31 million contract with funding and technical support from the Biomedical Advanced Research and Development Authority. HHS said Monday the new vaccine, called NuThrax, will work to improve on the existing licensed vaccine as …
Read More »
GovCon Wire Your Direct Source for Government Contracting News